Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$3.19 USD
+0.23 (7.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.19 USD
+0.23 (7.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Editas Medicine (EDIT) Enters Oversold Territory
by Zacks Equity Research
Editas Medicine, Inc. (EDIT) has been on a bit of a cold streak lately
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (EDIT) Outperforming Other Medical Stocks This Year?
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Zacks Equity Research
Sector ETF report for ARKG
Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia
by Zacks Equity Research
Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia
CRISPR Science and Stocks: Knowing Enough to Invest
by Kevin Cook
Can you learn enough about the science and the companies to invest with confidence?
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is Editas Medicine, Inc. (EDIT) Outperforming Other Medical Stocks This Year?
Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex
by Zacks Equity Research
Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is Editas Medicine, Inc. (EDIT) Outperforming Other Medical Stocks This Year?
Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA
by Zacks Equity Research
FDA places clinical hold on a Vertex (VRTX) and CRISPR Therapeutics' IND application for CTX001 for the treatment of sickle cell disease.
Should You Buy the Dip in CRISPR Therapeutics?
by David Borun
A "Clinical Hold" from the FDA has the shares falling, but is it an opportunity to get in?
Is Genome Editing the Next Biotech Breakthrough?
by David Borun
CRISPR technology is promising to be the foundation the treatment of 1000s of diseases
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is Editas Medicine, Inc. (EDIT) Outperforming Other Medical Stocks This Year?
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics
Why Sarepta (SRPT) Jumped and We Sold
by Kevin Cook
Gains have rewarded the patient, but the long-term is balanced with obstacles still ahead in the FDA gauntlet
Healthcare Heroes That Aren't Done Yet
by Kevin Cook
Key growth stocks across medical industries tell you the megatrends are in full force for years to come
Editas Medicine (EDIT) Surges: Stock Moves 13.2% Higher
by Zacks Equity Research
Editas Medicine (EDIT) was a big mover last session, as the company saw its shares rise more than 13% on the day amid huge volumes.
Bitcoin or CRISPR: Which is the Bigger Disruptor?
by Kevin Cook
In just 5 years, two new "exponential technologies" have been created that will dramatically change the world
What's in the Cards for Adverum (ADVM) This Earnings Season?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.
Editas Medicine (EDIT) Looks Good: Stock Moves Up 11.3%
by Zacks Equity Research
Editas Medicine, Inc. (EDIT) moved big moved last session, as its shares rose over 11% on the day.
What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?
by Zacks Equity Research
Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.
Why Editas Medicine (EDIT) Might Surprise This Earnings Season
by Zacks Equity Research
Investors are always looking for stocks that are poised to beat at earnings season and Editas Medicine, Inc. (EDIT) may be one such company.
Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?
by Zacks Equity Research
Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.
4 Drug Stocks Poised to Beat this Earnings Season
by Zacks Equity Research
M&A and licensing deals as well as drug pricing issues are expected to remain in focus in 2017.
What's in Store for Immune Design (IMDZ) Stock in Q1 Earnings?
by Zacks Equity Research
Immune Design Corp (IMDZ) is expected to report first-quarter 2017 results on May 9.
What's in Store for BioDelivery (BDSI) this Earnings Season?
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) is expected to report first-quarter 2017 results later this month. Last quarter, the company???s loss was wider than expected.